Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
142.09
+0.55 (0.39%)
At close: Apr 9, 2026, 4:00 PM EDT
142.09
0.00 (0.00%)
After-hours: Apr 9, 2026, 4:34 PM EDT
Gilead Sciences Revenue
In the year 2025, Gilead Sciences had annual revenue of $29.44B with 2.40% growth. Gilead Sciences had revenue of $7.93B in the quarter ending December 31, 2025, with 4.70% growth.
Revenue (ttm)
$29.44B
Revenue Growth
+2.40%
P/S Ratio
6.02
Revenue / Employee
$1,731,941
Employees
17,000
Market Cap
176.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.44B | 689.00M | 2.40% |
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | 22.45B | 322.00M | 1.46% |
| Dec 31, 2018 | 22.13B | -3.98B | -15.24% |
| Dec 31, 2017 | 26.11B | -4.28B | -14.09% |
| Dec 31, 2016 | 30.39B | -2.25B | -6.89% |
| Dec 31, 2015 | 32.64B | 7.75B | 31.13% |
| Dec 31, 2014 | 24.89B | 13.69B | 122.19% |
| Dec 31, 2013 | 11.20B | 1.50B | 15.46% |
| Dec 31, 2012 | 9.70B | 1.32B | 15.70% |
| Dec 31, 2011 | 8.39B | 435.97M | 5.48% |
| Dec 31, 2010 | 7.95B | 938.04M | 13.38% |
| Dec 31, 2009 | 7.01B | 1.68B | 31.40% |
| Dec 31, 2008 | 5.34B | 1.11B | 26.14% |
| Dec 31, 2007 | 4.23B | 1.20B | 39.78% |
| Dec 31, 2006 | 3.03B | 997.74M | 49.19% |
| Dec 31, 2005 | 2.03B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
GILD News
- 8 hours ago - Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE - Business Wire
- 9 hours ago - Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target Exercise - Business Wire
- 2 days ago - EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion - PRNewsWire
- 2 days ago - Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion - Barrons
- 2 days ago - Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion - WSJ
- 2 days ago - Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline - Business Wire
- 2 days ago - Gilead to acquire Tubulis GmbH for up to $5 billion - Reuters
- 8 days ago - Gilead Extends Tender Offer to Acquire Arcellx - Business Wire